{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:sildenafil",
  "owner": "cardio",
  "kind": "drug",
  "slug": "sildenafil",
  "name": "Sildenafil",
  "aliases": [
    "Sildenafil citrate",
    "Revatio"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Sildenafil, in the form sold as Revatio, is a phosphodiesterase 5 (PDE5) inhibitor. The US label for pulmonary arterial hypertension (PAH) (WHO Group I) lists, in adults, improving exercise ability and delaying clinical worsening and, separately, in pediatric patients 1 to 17 years old, improving exercise ability. This page covers the pulmonary arterial hypertension use. Sildenafil also has a separate US label for erectile dysfunction, which this page does not describe. The label says sildenafil inhibits an enzyme, PDE-5, in the smooth muscle of the lung blood vessels.",
  "summary_technical": "RxNorm ingredient 136411 (RxNorm also holds 221161, sildenafil citrate). MeSH D000068677 is named Sildenafil Citrate, with Sildenafil among its entry terms (a lookup on 2026-11-18, hash only), and carries no scope note, so it is recorded as an exact match for identity only. The openFDA label record for Revatio lists a UNII for the citrate, which is not recorded for the substance. RxClass lists the established pharmacologic class Phosphodiesterase 5 Inhibitor, so the record is filed under the PDE5 inhibitor page for pulmonary hypertension. The label read is the Viatris Specialty LLC label for Revatio, applications NDA203109, NDA022473 and NDA021845, effective 2024-12-18 in openFDA. The adult and pediatric statements sit in separate claims and contexts. The Viagra label (NDA020895, Viatris Specialty LLC, effective 2023-11-17) was read only for its first indication sentence. A maternal atlas page for sildenafil exists and is a separate record. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "136411",
      "normalized_value": "136411",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D000068677",
      "normalized_value": "D000068677",
      "match": "exact",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": "Sildenafil Citrate",
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says sildenafil is an inhibitor of cGMP specific PDE-5 in the smooth muscle of the pulmonary vasculature."
  },
  "content_digest": "c8b03238726a3a5664c5c6bc1af234a820ad820ea08662ca335fe75f0146eab3",
  "review": {
    "content_digest": "c8b03238726a3a5664c5c6bc1af234a820ad820ea08662ca335fe75f0146eab3",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-revatio-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:sildenafil",
      "category": "descriptive",
      "statement": "The US label of Revatio (sildenafil citrate, Viatris Specialty LLC, applications NDA203109, NDA022473 and NDA021845; the version dated 2024-12-18 in openFDA) lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.",
      "context": {
        "id": "cardio:ctx-fda-revatio-label-us",
        "label": "Adults with pulmonary arterial hypertension, as described in the US label of Revatio",
        "recipient": "adult",
        "population": "Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Revatio label for pulmonary arterial hypertension. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA203109.",
          "snapshot": {
            "id": "cardio:openfda-label-revatio-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:36Z",
            "content_hash": "26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb",
            "source_effective_date": "2024-12-18",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-revatio",
            "source_type": "regulator",
            "title": "openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-revatio.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241218.",
          "snapshot": {
            "id": "cardio:openfda-label-revatio-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:36Z",
            "content_hash": "26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb",
            "source_effective_date": "2024-12-18",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-revatio",
            "source_type": "regulator",
            "title": "openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-revatio.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-SIL-LB-03, Q-K30-SIL-LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-revatio-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:36Z",
            "content_hash": "26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb",
            "source_effective_date": "2024-12-18",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-revatio",
            "source_type": "regulator",
            "title": "openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-revatio.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "d41c0e2a457fc78f4639dced4cbebe17f2b053111df0a4203fa4748497dea893",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-revatio-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-revatio-label-paediatric",
      "owner": "cardio",
      "subject_entity_id": "cardio:sildenafil",
      "category": "descriptive",
      "statement": "The same US label of Revatio separately lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old, to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, a measure of pulmonary hemodynamics.",
      "context": {
        "id": "cardio:ctx-fda-revatio-label-paediatric",
        "label": "Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio",
        "recipient": "child",
        "population": "Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Pediatric patients 1 to 17 years old, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Revatio label for children aged 1 to 17 years. It says nothing about newborns or children under 1 year. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA203109.",
          "snapshot": {
            "id": "cardio:openfda-label-revatio-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:36Z",
            "content_hash": "26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb",
            "source_effective_date": "2024-12-18",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-revatio",
            "source_type": "regulator",
            "title": "openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-revatio.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241218.",
          "snapshot": {
            "id": "cardio:openfda-label-revatio-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:36Z",
            "content_hash": "26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb",
            "source_effective_date": "2024-12-18",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-revatio",
            "source_type": "regulator",
            "title": "openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-revatio.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-SIL-LB-05, Q-K30-SIL-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-revatio-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:36Z",
            "content_hash": "26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb",
            "source_effective_date": "2024-12-18",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-revatio",
            "source_type": "regulator",
            "title": "openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-revatio.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "e28c79b671944e3735f9b3e735219826f3a15c944418589407f2112cf3da670d",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-revatio-label-paediatric.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Sildenafil is a phosphodiesterase 5 inhibitor (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:pde5-inhibitors-for-pulmonary-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-136411-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to improve exercise ability and delay clinical worsening, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-revatio-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label separately lists pulmonary arterial hypertension in pediatric patients 1 to 17 years old as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-revatio-label-paediatric",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/sildenafil/",
  "context_path": "api/v1/context/cardio--sildenafil.md"
}
